US2010076179A1PendingUtilityA1

Antibodies to mammalian cytokine-like factor 7

73
Assignee: ZYMOGENETICS INCPriority: Apr 25, 1997Filed: Sep 16, 2009Published: Mar 25, 2010
Est. expiryApr 25, 2017(expired)· nominal 20-yr term from priority
Inventors:Scott R. PresnellTeresa Gilbert
C07K 14/52C07K 2319/00C07K 2319/02
73
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Novel mammalian zcyto7 polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods including antibodies and anti-idiotypic antibodies.

Claims

exact text as granted — not AI-modified
1 . An isolated antibody or binding fragment thereof that specifically binds to a polypeptide consisting of amino acid residues 21-180 of SEQ ID NO:2. 
     
     
         2 . The isolated antibody or binding fragment of  claim 1 , wherein the isolated antibody or binding fragment is a monoclonal antibody. 
     
     
         3 . The isolated antibody or binding fragment of  claim 1 , wherein the isolated antibody or binding fragment is a polyclonal antibody. 
     
     
         4 . The isolated antibody or binding fragment of  claim 1 , wherein the isolated antibody or binding fragment is humanized. 
     
     
         5 . The isolated antibody or binding fragment of  claim 4 , wherein the humanized antibody or binding fragment has non-human complementarity determining regions (CDRs) grafted onto a human framework and constant regions. 
     
     
         6 . The isolated antibody or binding fragment of  claim 4 , wherein the variable domains of the humanized antibody or binding fragment are of non-human origin. 
     
     
         7 . The isolated antibody or binding fragment of  claim 1 , wherein the isolated antibody or binding fragment binds to the polypeptide with a K a  of greater than or equal to 10 7 /M. 
     
     
         8 . The isolated antibody or binding fragment of  claim 7 , wherein the isolated antibody or binding fragment binds to the polypeptide with a K a  of greater than 10 9 /M. 
     
     
         9 . The isolated antibody or binding fragment of  claim 1 , wherein the isolated binding fragment is an F(ab′) 2  or Fab fragment. 
     
     
         10 . The isolated antibody or binding fragment of  claim 1 , wherein the isolated antibody or binding fragment is genetically engineered. 
     
     
         11 . The isolated antibody or binding fragment of  claim 10 , wherein the genetically engineered antibody or binding fragment is a chimeric antibody, Fv fragment, single-chain antibody, or synthetic antigen-binding peptide or polypeptide. 
     
     
         12 . The isolated antibody or binding fragment of  claim 1 , wherein the isolated antibody or binding fragment further comprises an affinity tag. 
     
     
         13 . The isolated antibody or binding fragment of  claim 12 , wherein the affinity tag is a poly-histidine tract, protein A, glutathione S transferase, Glu-Glu affinity tag, substance P, FLAG™ peptide, streptavidin binding peptide, or other antigenic epitope or binding domain. 
     
     
         14 . The isolated antibody or binding fragment of  claim 1 , wherein the isolated antibody or binding fragment further comprises a drug, toxin, or radionuclide. 
     
     
         15 . A pharmaceutical composition comprising the antibody or binding fragment of  claim 1 .

Join the waitlist — get patent alerts

Track US2010076179A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.